Citations

Clear

382 citation(s) found for "Li, Man".

A Roadmap for Therapeutic Discovery in Pulmonary Hypertension Associated with Left Heart Failure. A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Pulmonary Circulation & Right Ventricular Function
Pollesello, Piero , Anker, Markus S. , Backs, Johannes , Bayés‐Genís, Antoni , González, Aránzazu , Maack, Cristoph, Madden, Brendan , Redfield, Margaret M. , Rich, Stuart , Schiattarella, Gabriele G. , Skaara, Hall, Stellos, Konstantinos , Vachiéry, Jean Luc, Meer, Peter van der, Linthout, Sophie Van , Pruszczyk, Piotr , Seferović, Petar , Metra, Marco , Rosano, Giuseppe, Tocchetti, Carlo G. , Schiattarella, Gabriele G. , Stellos, Konstantinos , Metra, Marco , Tocchetti, Carlo Gabriele , Ameri, Pietro , Mercurio, Valentina , Borlaug, Barry A. , Burkhoff, Daniel , Caravita, Sergio , Chan, Stephen Y. , Man, Frances S. de , Giannakoulas, George , Guazzi, Marco , Hassoun, Paul M. , Hemnes, Anna R. , Melenovský, Vojtěch , Müller, Oliver Josef , Papp, Zoltán , Pullamsetti, Soni Savai , Rainer, Peter P. , Tedford, Ryan J. , Thum, Thomas , Vachiéry, Jean‐Luc , Meer, Peter van der , Coats, Andrew J.S. , Rosenkranz, Stephan

Mayo Clinic

European Journal of Heart Failure | April 19, 2024 | Volume: 26 | Issue: 4 | Pages: 707-729

10.1002/ejhf.3236 | PMID 38639017 Get It

Abstract Pulmonary hypertension (PH) associated with left heart failure (LHF) (PH-LHF) is one of the most common causes of PH. It directly contributes to symptoms and reduced functional capacity and negatively affects right heart function, ultimately leading to a poor prognosis. There are no specific treatments for PH-LHF, despite the high number of drugs tested so far. This scientific document addresses the main knowledge gaps in PH-LHF with emphasis on pathophysiology and clinical trials. Key identified issues include better understanding of the role of pulmonary venous versus arteriolar remodelling, multidimensional phenotyping to recognize patient subgroups positioned to respond to different therapies, and conduct of rigorous pre-clinical studies combining small and large animal models. Advancements in these areas are expected to better inform the design of clinical trials and extend treatment options beyond those effective in pulmonary arterial hypertension. Enrichment strategies, endpoint assessments, and thorough haemodynamic studies, both at rest and during exercise, are proposed to play primary roles to optimize early-stage development of candidate therapies for PH-LHF.
A large language model–based generative natural language processing framework fine‐tuned on clinical notes accurately extracts headache frequency from electronic health records
Chiang, Chia‐Chun , Luo, Man , Dumkrieger, Gina , Trivedi, Shubham , Chen, Yi‐Chieh , Chao, Chieh‐Ju , Schwedt, Todd J. , Sarker, Abeed , Banerjee, Imon , Banerjee, Imon , Chiang, Chia-Chun , Schwedt, Todd J , Dumkrieger, Gina , Chao, Chieh-Ju , Chen, Yi-Chieh

Mayo Clinic

Headache: The Journal of Head and Face Pain | March 25, 2024 | Volume: 64 | Issue: 4 | Pages: 400-409

10.1111/head.14702 | PMID 38525734 Get It

Abstract Objective To develop a natural language processing (NLP) algorithm that can accurately extract headache frequency from free‐text clinical notes. Background Headache frequency, defined as the number of days with any headache in a month (or 4 weeks), remains a key parameter in the evaluation of treatment response to migraine preventive medications. However, due to the variations and inconsistencies in documentation by clinicians, significant challenges exist to accurately extract headache frequency from the electronic health record (EHR) by traditional NLP algorithms. Methods This was a retrospective cross‐sectional study with patients identified from two tertiary headache referral centers, Mayo Clinic Arizona and Mayo Clinic Rochester. All neurology consultation notes written by 15 specialized clinicians (11 headache specialists and 4 nurse practitioners) between 2012 and 2022 were extracted and 1915 notes were used for model fine‐tuning (90%) and testing (10%). We employed four different NLP frameworks: (1) ClinicalBERT (Bidirectional Encoder Representations from Transformers) regression model, (2) Generative Pre‐Trained Transformer‐2 (GPT‐2) Question Answering (QA) model zero‐shot, (3) GPT‐2 QA model few‐shot training fine‐tuned on clinical notes, and (4) GPT‐2 generative model few‐shot training fine‐tuned on clinical notes to generate the answer by considering the context of included text. Results The mean (standard deviation) headache frequency of our training and testing datasets were 13.4 (10.9) and 14.4 (11.2), respectively. The GPT‐2 generative model was the best‐performing model with an accuracy of 0.92 (0.91, 0.93, 95% confidence interval [CI]) and R 2 score of 0.89 (0.87, 0.90, 95% CI), and all GPT‐2–based models outperformed the ClinicalBERT model in terms of exact matching accuracy. Although the ClinicalBERT regression model had the lowest accuracy of 0.27 (0.26, 0.28), it demonstrated a high R 2 score of 0.88 (0.85, 0.89), suggesting the ClinicalBERT model can reasonably predict the headache frequency within a range of ≤ ± 3 days, and the R 2 score was higher than the GPT‐2 QA zero‐shot model or GPT‐2 QA model few‐shot training fine‐tuned model. Conclusion We developed a robust information extraction model based on a state‐of‐the‐art large language model, a GPT‐2 generative model that can extract headache frequency from EHR free‐text clinical notes with high accuracy and R 2 score. It overcame several challenges related to different ways clinicians document headache frequency that were not easily achieved by traditional NLP models. We also showed that GPT‐2–based frameworks outperformed ClinicalBERT in terms of accuracy in extracting headache frequency from clinical notes. To facilitate research in the field, we released the GPT‐2 generative model and inference code with open‐source license of community use in GitHub. Additional fine‐tuning of the algorithm might be required when applied to different health‐care systems for various clinical use cases.
First‐in‐man report of transsubclavian venous implantation of the Aveir leadless cardiac pacing system
Ward, Robert C. , Amin, Hina , Noseworthy, Peter A. , Asirvatham, Samuel J. , Friedman, Paul A. , Mulpuru, Siva K. , Balanescu, Dinu V , Ward, Robert C , Noseworthy, Peter A , Asirvatham, Samuel J , Friedman, Paul A , Mulpuru, Siva K , Balanescu, Dinu Valentin

Mayo Clinic

Journal of Cardiovascular Electrophysiology | March 11, 2024 | Volume: 35 | Issue: 5 | Pages: 1041-1045

10.1111/jce.16241 | PMID 38462703 Get It

Abstract Introduction Transsubclavian venous implantation of the Aveir leadless cardiac pacemaker (LCP) has not been previously reported. Methods and Results Three cases of transsubclavian implantation of the Aveir LCP are reported. Two cases were postbilateral orthotopic lung transplant, without appropriate femoral or jugular access due to recent ECMO cannulation and jugular central venous catheters. In one case, there was strong patient preference for same‐day discharge. Stability testing confirmed adequate fixation and electrical testing confirmed stable parameters in all cases. All patients tolerated the procedure well without significant immediate complications. Conclusions We demonstrate the feasibility of transsubclavian implantation of the Aveir LCP.
Genetic correlations of alcohol consumption and alcohol use disorder with sex hormone levels in females and males
Waller, Cameron, Ho, Ada Man‐Choi , Batzler, Anthony , Geske, Jennifer R. , Ho, Ada, Geske, Jennifer, Winham, Stacey, Ho, Ada M-C , Geske, Jennifer , Karpyak, Victor M. , Biernacka, Joanna M. , Winham, Stacey J.

Mayo Clinic

No container title available | February 28, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-3944066/v1 | PMID 38464231 Get It

Abstract Background Alcohol consumption behaviors and alcohol use disorder risk and presentation differ by sex, and these complex traits are associated with blood concentrations of the steroid sex hormones, testosterone and estradiol, and their regulatory binding proteins, sex hormone binding globulin (SHBG) and albumin. Genetic variation is associated with alcohol consumption and alcohol use disorder, as well as levels of steroid sex hormones and their binding proteins. Methods To assess the contribution of genetic factors to previously described phenotypic associations between alcohol-use traits and sex-hormone levels, we estimated genetic correlations (rg) using summary statistics from prior published, large sample size genome-wide association studies (GWAS) of alcohol consumption, alcohol dependence, testosterone, estradiol, SHBG, and albumin. Results For alcohol consumption, we observed positive genetic correlation (i.e. genetic effects in the same direction) with total testosterone in males (rg = 0.084, p = 0.007) and trends toward positive genetic correlation with bioavailable testosterone (rg = 0.060, p = 0.084) and SHBG in males (rg = 0.056, p = 0.086) and with albumin in a sex-combined cohort (rg = 0.082, p = 0.015); however in females, we observed positive genetic correlation with SHBG (rg = 0.089, p = 0.004) and a trend toward negative genetic correlation (i.e. genetic effects in opposite directions) with bioavailable testosterone (rg = -0.064, p = 0.032). For alcohol dependence, we observed a trend toward negative genetic correlation with total testosterone in females (rg = -0.106, p = 0.024) and positive genetic correlation with BMI-adjusted SHBG in males (rg = 0.119, p = 0.017). Several of these genetic correlations differed between females and males and were not in the same direction as the corresponding phenotypic associations. Conclusions Findings suggest that shared genetic effects may contribute to positive associations of alcohol consumption with albumin in both sexes, as well as positive associations between alcohol consumption and bioavailable testosterone and between alcohol dependence and SHBG in males. However, relative contributions of heritable and environmental factors to associations between alcohol-use traits and sex-hormone levels may differ by sex, with genetic factors contributing more in males and environmental factors contributing more in females.
Four weeks SGLT2 inhibition improves beta cell function and glucose tolerance without affecting muscle free fatty acid or glucose uptake in subjects with type 2 diabetes
Voigt, Jens Hohwü , Pedersen, Steen B. , Møller, Niels , Jessen, Niels , Man, Chiara Dalla , Gormsen, Lars Christian , Søndergaard, Esben , LAURENTI, MARCELLO C. , Dalla Man, Chiara , Møller, Niels , Lauritsen, Katrine Meyer , Hansen, Troels Krarup , Vella, Adrian

Mayo Clinic

Basic & Clinical Pharmacology & Toxicology | February 27, 2024 | Volume: 134 | Issue: 5 | Pages: 643-656

10.1111/bcpt.13991 | PMID 38409617 Get It

AbstractAimsSodium glucose co‐transporter‐2 (SGLT2) inhibition lowers glucose levels independently of insulin, leading to reduced insulin secretion and increased lipolysis, resulting in elevated circulating free fatty acids (FFAs). While SGLT2 inhibition improves tissue insulin sensitivity, the increase in circulating FFAs could reduce insulin sensitivity in skeletal muscle and the liver. We aimed to investigate the effects of SGLT2 inhibition on substrate utilization in skeletal muscle and the liver and to measure beta‐cell function and glucose tolerance.MethodsThirteen metformin‐treated individuals with type 2 diabetes were randomized to once‐daily empagliflozin 25 mg or placebo for 4 weeks in a crossover design. Skeletal muscle glucose and FFA uptake together with hepatic tissue FFA uptake were measured using [18F]FDG positron emission tomography/computed tomography (PET/CT) and [11C]palmitate PET/CT. Insulin secretion and action were estimated using the oral minimal model.ResultsEmpagliflozin did not affect glucose (0.73 ± 0.30 vs. 1.16 ± 0.64, μmol/g/min p = 0.11) or FFA (0.60 ± 0.30 vs. 0.56 ± 0.3, μmol/g/min p = 0.54) uptake in skeletal muscle. FFA uptake in the liver (21.2 ± 10.1 vs. 19 ± 8.8, μmol/100 ml/min p = 0.32) was unaffected.Empagliflozin increased total beta‐cell responsivity (20 ± 8 vs. 14 ± 9, 10−9 min−1, p < 0.01) and glucose effectiveness (2.6 × 10−2 ± 0.3 × 10−2 vs. 2.4 × 10−2 ± 0.3 × 10−2, dL/kg/min, p = 0.02).ConclusionsDespite improved beta‐cell function and glucose tolerance, empagliflozin does not appear to affect skeletal muscle FFA or glucose uptake.
Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice
Lounev, Vitali, Groppe, Jay C. , Brewer, Niambi , Wentworth, Kelly L. , Smith, Victoria , Xu, Meiqi , Schomburg, Lutz , Bhargava, Pankaj , Mukaddam, Mona Al , Shore, Eileen M. , Pignolo, Robert J. , Hsiao, Edward C. , Kaplan, Frederick S.

Mayo Clinic

Journal of Bone and Mineral Research | February 17, 2024 | Volume: 39 | Issue: 4 | Pages: 382-398

10.1093/jbmr/zjae029 | PMID 38477818 Get It

Abstract Single case studies of extraordinary disease resilience may provide therapeutic insight into conditions for which no definitive treatments exist. An otherwise healthy 35-year-old man (patient-R) with the canonical pathogenic ACVR1R206H variant and the classic congenital great toe malformation of fibrodysplasia ossificans progressiva (FOP) had extreme paucity of post-natal heterotopic ossification (HO) and nearly normal mobility. We hypothesized that patient-R lacked a sufficient post-natal inflammatory trigger for HO. A plasma biomarker survey revealed a reduction in total matrix metalloproteinase-9 (MMP-9) compared to healthy controls and individuals with quiescent FOP. Whole exome sequencing identified compound heterozygous variants in MMP-9 (c.59C &gt; T, p.A20V and c.493G &gt; A, p.D165N). Structural analysis of the D165N variant predicted both decreased MMP-9 secretion and activity that were confirmed by enzyme-linked immunosorbent assay and gelatin zymography. Further, human proinflammatory M1-like macrophages expressing either MMP-9 variant produced significantly less Activin A, an obligate ligand for HO in FOP, compared to wildtype controls. Importantly, MMP-9 inhibition by genetic, biologic, or pharmacologic means in multiple FOP mouse models abrogated trauma-induced HO, sequestered Activin A in the extracellular matrix (ECM), and induced regeneration of injured skeletal muscle. Our data suggest that MMP-9 is a druggable node linking inflammation to HO, orchestrates an existential role in the pathogenesis of FOP, and illustrates that a single patient’s clinical phenotype can reveal critical molecular mechanisms of disease that unveil novel treatment strategies.
Abstract TMP6: Dural Arteriovenous Fistulas With Cognitive Impairment: Angiographic Characteristics and Treatment Outcomes
Sanchez, Sebastian , Sagues, Elena , Gudino, Andres, Saleem, Arshaq, Sheehan, Jason P. , Kim, Louis J. , Meyer, R. Michael, Guniganti, Ridhima , Kansagra, Akash P. , Brinjikji, Waleed , Durnford, Andrew , Polifka, Adam , Gross, Bradley A. , Alaraj, Ali , Kwasnicki, Amanda , Starke, Robert M., Chen, Stephanie H. , Potgieser, Adriaan R. E., Satomi, Junichiro, Tada, Yoshiteru , Winkler, Ethan A. , Zipfel, Gregory J. , Alaraj, Ali , Ojeda, Diego, Gudino, Andres , Saleem, Arshaq , Wendt, Linder , Hayakawa, M. , Chen, Ching‐Jen , Kim, Louis J. , Abecassis, Isaac Josh , Levitt, Michael R. , Lanzino, Giuseppe , Giordan, Enrico , Bulters, Diederik , Fox, W Christopher , Smith, Jessica , Gross, Bradley , Amin-Hanjani, Sepideh , van DijK, J Marc C , Phelps, Ryan , Abla, Adib A. , Du, Rose , Lai, Pui Man Rosalind , Ortega-Gutierrez, Santiago , Derdeyn, Colin P. , Samaniego, Edgar A

Mayo Clinic

Stroke | February 1, 2024 | Volume: 55 | Issue: Suppl_1 | Pages: No page available

10.1161/str.55.suppl_1.tmp6 Get It

Background: Anecdotal cases of rapidly progressing dementia in patients with dural arteriovenous fistulas (dAVFs) and cortical venous drainage have been reported in small series. However, a comprehensive description of the angiographic features of this dAVFs is lacking. We conducted an analysis of the largest cohort of dAVFs presenting with cognitive impairment (dAVFs-CI), aiming to provide a better characterization of this subset of dAVFs. Methods: The CONDOR Consortium, a multicenter repository comprising 1077 dAVFs, served as the study population. Among the dAVFs, patients with dAVFs-CI were analyzed. A propensity scores matching analysis was conducted to compare dAVFs-CI with Borden type II and type III dAVFs without cognitive impairment (controls). Logistic regression was employed to identify angiographic characteristics specific to dAVFs-CI. Post-treatment outcomes were analyzed. Results: A total of 60 patients with dAVFs-CI and 60 control dAVFs were included. Outflow obstruction leading to venous hypertension was observed in all dAVFs-CI. Sinus stenosis was significantly associated with dAVFs-CI (OR 2.85, 95% CI: 1.16-7.55, p = 0.027). dAVFs-CI were more likely to have a higher number of arterial feeders (OR 1.56, 95% CI 1.22-2.05, p < 0.001) and draining veins (OR 2.05, 95% CI 1.05-4.46, p = 0.004). Venous ectasia increased the risk of dAVFs-CI (OR 2.38, 95% CI 1.13-5.11, p = 0.024). A trend toward achieving asymptomatic status at follow-up was observed in patients with successful closure of dAVFs (OR 2.86, 95% CI 0.85-9.56, p = 0.09). Discussion: Venous hypertension is a key angiographic feature dAVFs-CI. dAVFs-CI exhibit a complex angioarchitecture characterized by an increased number of arteriovenous connections and stenosed sinuses. The presence of venous ectasia further exacerbates the impaired drainage and contributes to the development of dAVFs-CI. Notably, closure of the dAVF has the potential to reverse symptoms in certain cases (Figure).
LoST: A Mental Health Dataset of Low Self-Esteem in Reddit Posts
Garg, Muskan, Goswami, Raxit, Sohn, Sunghwan , Gaur, Manas

Mayo Clinic

2023 IEEE International Conference on Systems, Man, and Cybernetics (SMC) | January 29, 2024 | Volume: No volume available | Issue: No issue available | Pages: 3854-3859

10.1109/smc53992.2023.10394671 | PMID 38524640 Get It

TREM2‐IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke
Yang, Sheng , Qin, Chuan, Chu, Yun‐Hui, Tang, Yue , Zhou, Luo‐Qi , Zhang, Hang , Dong, Ming‐Hao , Pang, Xiao‐Wei, Chen, Lian , Wu, Long‐Jun , Wang, Wei , Wang, Wei , Wu, Long-Jun , Qin, Chuan, Chen, Man , Tian, Dai‐Shi

Mayo Clinic

Advanced Science | December 27, 2023 | Volume: 11 | Issue: 10 | Pages: No page available

10.1002/advs.202305614 | PMID 38151703 Get It

Abstract Microglia, the major resident immune cells in the central nervous system, serve as the frontline soldiers against cerebral ischemic injuries, possibly along with metabolic alterations. However, signaling pathways involved in the regulation of microglial immunometabolism in ischemic stroke remain to be further elucidated. In this study, using single‐nuclei RNA sequencing, a microglial subcluster up‐regulated in ischemic brain tissues is identified, with high expression of Igf1 and Trem2, neuroprotective transcriptional signature and enhanced oxidative phosphorylation. Microglial depletion by PLX3397 exacerbates ischemic brain damage, which is reversed by repopulating the microglia with high Igf1 and Trem2 phenotype. Mechanistically, Igf1 serves as one of the major down‐stream molecules of Trem2, and Trem2‐Igf1 signaling axis regulates microglial functional and metabolic profiles, exerting neuroprotective effects on ischemic stroke. Overexpression of Igf1 and supplementation of cyclocreatine restore microglial glucometabolic levels and cellular functions even in the absence of Trem2. These findings suggest that Trem2‐Igf1 signaling axis reprograms microglial immunometabolic profiles and shifts microglia toward a neuroprotective phenotype, which has promising therapeutic potential in treating ischemic stroke.
Gynecomastia in a Man With Adrenal Mass
Saini, Jasmine , Navin, Patrick J. , Rivera, Michael , Navin, Patrick , Bancos, Irina , Saini, Jasmine , Bancos, Irina

Mayo Clinic

JCEM Case Reports | December 20, 2023 | Volume: 2 | Issue: 1 | Pages: No page available

10.1210/jcemcr/luad143 | PMID 38192879 Get It

Abstract Estrogen-secreting adrenocortical carcinoma (ACC) is exceedingly rare, representing 1% to 2% of all ACCs. We present a case of a 65-year-old man diagnosed with an estrogen-secreting, 4.3-cm right adrenal mass discovered during work-up for bilateral gynecomastia. Gynecomastia and hyperestrogenism resolved after laparoscopic adrenalectomy, and pathology was reported as adrenocortical adenoma. However, 5 years later, he again developed bilateral gynecomastia because of recurrent hyperestrogenism. Imaging revealed multiple metastases in the abdomen. Urine steroid profiling demonstrated increased androgen precursors, androgen metabolites, and glucocorticoid precursors. Ultrasound-guided biopsy of one of the metastases confirmed ACC. Initial therapy included debulking surgery with removal of metastatic lesions. Mitotane therapy was initiated 4 weeks later along with hydrocortisone for anticipated mitotane-induced adrenal insufficiency. Histopathology from the adrenalectomy specimen 5 years earlier was rereviewed and confirmed ACC. Estrogen-secreting adrenal tumors are exceedingly rare, and the majority are malignant. This case underlines the importance of making an initial accurate diagnosis of adrenal malignancy that allows better surgical planning and appropriate monitoring. Indeterminate imaging characteristics of the adrenal mass, as well as the presentation with estrogen excess, suggested an elevated risk for ACC. Initial pathology-based misdiagnosis illustrates the need for an expert adrenal pathologist to review these rare tumors.